PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|September 10, 2010
Elan Drug Technologies Corporate Profile
Elan Drug Technologies, the world?s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products.
Advertisement
Elan Drug Technologies, the world’s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products. With over 40 years experience in the drug delivery business, we have successfully brought 36 drugs to market for clients in over 100 markets. We have successful collaborations with the majority of the world’s leading pharma companies with client annual in-market sales of over $3 billion.
Drug optimization, development and manufacture
Elan has a unique platform of technologies to offer our clients - from oral controlled release, delayed release, pulsatile release delivery systems to technology solutions for poorly water soluble compounds. We have a complete range of capabilities from formulation development through to commercial scale manufacture in modern facilities. Our technologies are supported by a robust patent estate of over 1,900 patents / patent applications. Elan has developed unique capabilities to from early stage development right through to full scale final dosage form manufacture.
INVITATION TO MEET WITH US
Join us at CPhI Worldwide Annual meeting from October 5-7 in Paris where we will at booth location 5D63. To organise a meeting e-mail us at
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement